• Created by Unknown User (alin314_1@touchstonenetwork.net), last modified on Jan 18, 2015 21:07

Mutant-Specific Epidermal Growth Factor Receptor Inhibitors

T790M Mutations: Understanding Resistance to EGFR Tyrosine Kinase Inhibitor Therapy

 

 



  File Modified
PDF File 1-s2.0-S1574789111001451-main.pdf Jan 13, 2015 18:32 by alin314_1@touchstonenetwork.net
PDF File fonc-04-00350.pdf Jan 13, 2015 18:33 by alin314_1@touchstonenetwork.net
PDF File BTT-40567-clinical-and-comparative-utility-of-afatinib-in-nsclc_042314 (1).pdf Jan 13, 2015 18:33 by alin314_1@touchstonenetwork.net
PDF File 40-49 TLCR-2012-44.pdf Jan 13, 2015 18:33 by alin314_1@touchstonenetwork.net
PDF File 2213-0802-2-2.pdf Jan 13, 2015 18:33 by alin314_1@touchstonenetwork.net
PDF File PIIS2211124714003015.pdf Jan 13, 2015 18:37 by alin314_1@touchstonenetwork.net
PDF File PIIS0305737214001200.pdf Jan 13, 2015 18:37 by alin314_1@touchstonenetwork.net
PDF File Epidermal growth factor receptor (EGFR) mutations in lung cancer Jan 13, 2015 18:54 by alin314_1@touchstonenetwork.net
PDF File Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance Jan 13, 2015 18:54 by alin314_1@touchstonenetwork.net
PDF File LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Jan 13, 2015 18:55 by alin314_1@touchstonenetwork.net
PDF File Target Binding Properties and Cellular Activity of Afatinib Jan 13, 2015 18:55 by alin314_1@touchstonenetwork.net

  • No labels